MY187802A - Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction - Google Patents

Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Info

Publication number
MY187802A
MY187802A MYPI2015002531A MYPI2015002531A MY187802A MY 187802 A MY187802 A MY 187802A MY PI2015002531 A MYPI2015002531 A MY PI2015002531A MY PI2015002531 A MYPI2015002531 A MY PI2015002531A MY 187802 A MY187802 A MY 187802A
Authority
MY
Malaysia
Prior art keywords
bimatoprost
sustained release
prostamides
prostaglandins
analogs
Prior art date
Application number
MYPI2015002531A
Other languages
English (en)
Inventor
David F Woodward
Scott M Whitcup
Patrick M Hughes
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MY187802A publication Critical patent/MY187802A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts or implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
MYPI2015002531A 2013-04-12 2014-04-09 Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction MY187802A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361811682P 2013-04-12 2013-04-12

Publications (1)

Publication Number Publication Date
MY187802A true MY187802A (en) 2021-10-26

Family

ID=51686960

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015002531A MY187802A (en) 2013-04-12 2014-04-09 Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Country Status (18)

Country Link
US (2) US20140308354A1 (enExample)
EP (2) EP2983663B1 (enExample)
JP (1) JP2016520561A (enExample)
KR (1) KR20150141972A (enExample)
CN (2) CN110840899A (enExample)
AU (2) AU2014250937A1 (enExample)
BR (1) BR112015025915A8 (enExample)
CA (1) CA2908731A1 (enExample)
CL (1) CL2015003023A1 (enExample)
DK (1) DK2983663T3 (enExample)
ES (1) ES2785382T3 (enExample)
IL (1) IL242006B (enExample)
MX (1) MX381097B (enExample)
MY (1) MY187802A (enExample)
RU (1) RU2015143859A (enExample)
SG (2) SG10201701938PA (enExample)
WO (1) WO2014169075A1 (enExample)
ZA (1) ZA201507217B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6796601B2 (ja) * 2015-04-30 2020-12-09 アラーガン、インコーポレイテッドAllergan,Incorporated 脂肪を低減させるための美容上の方法及び治療用途
US11452703B2 (en) * 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers
US12004995B2 (en) * 2020-07-21 2024-06-11 Allergan, Inc. Intraocular implant with high loading of a prostamide
EP4698184A1 (en) * 2023-04-18 2026-02-25 Welfare Concepts Limited Composition and method for inducing luteolysis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2218424A (en) * 1931-05-07 1940-10-15 Teleregister Corp Transmitter and code translator
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
DE69613693T2 (de) * 1995-05-18 2002-05-16 Allergan Sales, Inc. 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes
EP1562604B1 (en) 2002-10-23 2012-01-04 Sucampo AG Prostaglandin compounds for the treatment of obesity
CN101336887A (zh) * 2002-12-04 2009-01-07 参天制药株式会社 结膜下给药用药物组合物
EP1699432A2 (en) * 2003-12-22 2006-09-13 Aventis Pharmaceuticals, Inc. Injectable phosphatidylcholine preparations
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US7666912B2 (en) * 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
WO2011109384A2 (en) * 2010-03-02 2011-09-09 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
US20120022137A1 (en) 2010-07-21 2012-01-26 Rivers Hongwen M METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
TWI631961B (zh) * 2013-03-15 2018-08-11 美商歐樂根公司 含有前列醯胺之眼內植入物
JP6796601B2 (ja) 2015-04-30 2020-12-09 アラーガン、インコーポレイテッドAllergan,Incorporated 脂肪を低減させるための美容上の方法及び治療用途

Also Published As

Publication number Publication date
KR20150141972A (ko) 2015-12-21
JP2016520561A (ja) 2016-07-14
US20160339039A1 (en) 2016-11-24
SG10201701938PA (en) 2017-04-27
AU2014250937A1 (en) 2015-10-22
MX381097B (es) 2025-03-12
SG10202109919PA (en) 2021-10-28
EP3656375A1 (en) 2020-05-27
HK1221406A1 (en) 2017-06-02
AU2019203214B2 (en) 2020-10-29
RU2015143859A (ru) 2017-05-16
CA2908731A1 (en) 2014-10-16
BR112015025915A2 (pt) 2017-07-25
RU2015143859A3 (enExample) 2018-03-05
DK2983663T3 (da) 2020-04-20
CL2015003023A1 (es) 2016-06-10
AU2019203214A1 (en) 2019-05-30
ES2785382T3 (es) 2020-10-06
MX2015014320A (es) 2015-12-08
BR112015025915A8 (pt) 2020-01-14
EP2983663A1 (en) 2016-02-17
NZ712804A (en) 2021-02-26
CN105101962A (zh) 2015-11-25
IL242006B (en) 2020-04-30
US10682361B2 (en) 2020-06-16
US20140308354A1 (en) 2014-10-16
EP2983663B1 (en) 2020-01-22
ZA201507217B (en) 2017-09-27
WO2014169075A1 (en) 2014-10-16
CN110840899A (zh) 2020-02-28

Similar Documents

Publication Publication Date Title
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
CL2015003270A1 (es) Composiciones y métodos para el suministro tópico de prostaglandinas a la grasa subcutanea.
PH12015502546A1 (en) 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
EA201500852A1 (ru) Формы метил {4,6-диамино-2-[1-(2-фторбензил)-1н-пиразоло[3,4-в]пиридино-3-ил]пиримидино-5-ил}метил карбамата
MX2019005082A (es) Composiciones que comprenden 15-ohepa y metodos para usar las mismas.
PH12017500836A1 (en) Transdermal formulations
MX2014005510A (es) Nuevas composiciones, produccion de las mismas y uso de las mismas para la produccion de poliamidas coladas.
MX2016005596A (es) Ruta sintetica para obtener 2'-deoxi-2',2'-difluorotetrahidrouridi nas.
MX384131B (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos.
MX376782B (es) Métodos de administración de composiciones de amantadina.
MX369349B (es) Metodos para hacer inhibidores de la proteina deacetilasa.
MX2019010913A (es) Analogos de deutetrabenazina, su preparacion y uso.
BR112015025915A8 (pt) uso de composto para redução de gordura e composições
EA201691465A1 (ru) Средство для лечения сердечно-сосудистых заболеваний
MX2015011881A (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
EA201591449A1 (ru) Способы получения противораковых композиций
NO20161574A1 (en) Skiwax
MX2016002714A (es) Composicion y metodo para tropicalizar chocolate.
ES2586805T3 (es) Análogos de péptidos para tratar enfermedades y trastornos
MX2017006548A (es) Acido 2-octilciclopropil-1-carboxilico y sus isomeros y usos.